Figure 3
Figure 3. Development of pDC progenitors, pDCs, and cDCs in CXCR4 conditionally deficient mice. (A,B) Flow cytometric analysis of the numbers of LSK Flt3lo primitive hematopoietic cells, Flt3+ CLP, Flt3+ CMP pDC progenitors, and CD11cintB220+PDCA-1+ pDCs in bone marrow (n = 3) (A); and CD11cintB220+PDCA-1+ pDCs and CD11chiB220− cDCs in the spleen (B) in pIpC-treated MxCre/CXCR4f/wt mice, untreated MxCre/CXCR4f/null mice, and pIpC-treated MxCre/CXCR4f/null mice 3 weeks after the final pIpC treatment. (C) Bone marrow cells (Ly5.2+) from MxCre/CXCR4f/null or MxCre/CXCR4f/wt mice were transferred along with wild-type bone marrow cells (Ly5.1+) into lethally irradiated Ly5.1+ recipients. Chimeric mice were treated with pIpC at 13 weeks after transfer, and their bone marrow was analyzed by flow cytometry at 10 weeks after the treatment. The numbers of Ly5.2+ and Ly5.1+ CD11cintB220+PDCA-1+ pDCs are shown (n = 2). Error bars represent SD of the mean.

Development of pDC progenitors, pDCs, and cDCs in CXCR4 conditionally deficient mice. (A,B) Flow cytometric analysis of the numbers of LSK Flt3lo primitive hematopoietic cells, Flt3+ CLP, Flt3+ CMP pDC progenitors, and CD11cintB220+PDCA-1+ pDCs in bone marrow (n = 3) (A); and CD11cintB220+PDCA-1+ pDCs and CD11chiB220 cDCs in the spleen (B) in pIpC-treated MxCre/CXCR4f/wt mice, untreated MxCre/CXCR4f/null mice, and pIpC-treated MxCre/CXCR4f/null mice 3 weeks after the final pIpC treatment. (C) Bone marrow cells (Ly5.2+) from MxCre/CXCR4f/null or MxCre/CXCR4f/wt mice were transferred along with wild-type bone marrow cells (Ly5.1+) into lethally irradiated Ly5.1+ recipients. Chimeric mice were treated with pIpC at 13 weeks after transfer, and their bone marrow was analyzed by flow cytometry at 10 weeks after the treatment. The numbers of Ly5.2+ and Ly5.1+ CD11cintB220+PDCA-1+ pDCs are shown (n = 2). Error bars represent SD of the mean.

Close Modal

or Create an Account

Close Modal
Close Modal